EP1187633A4 - Use of anti-vegf antibody to enhance radiation in cancer therapy - Google Patents

Use of anti-vegf antibody to enhance radiation in cancer therapy

Info

Publication number
EP1187633A4
EP1187633A4 EP00931923A EP00931923A EP1187633A4 EP 1187633 A4 EP1187633 A4 EP 1187633A4 EP 00931923 A EP00931923 A EP 00931923A EP 00931923 A EP00931923 A EP 00931923A EP 1187633 A4 EP1187633 A4 EP 1187633A4
Authority
EP
European Patent Office
Prior art keywords
cancer therapy
vegf antibody
enhance radiation
enhance
radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00931923A
Other languages
German (de)
French (fr)
Other versions
EP1187633A1 (en
Inventor
Ralph R Weichselbaum
Donald W Kufe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, Arch Development Corp filed Critical Dana Farber Cancer Institute Inc
Publication of EP1187633A1 publication Critical patent/EP1187633A1/en
Publication of EP1187633A4 publication Critical patent/EP1187633A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
EP00931923A 1999-04-08 2000-04-07 Use of anti-vegf antibody to enhance radiation in cancer therapy Withdrawn EP1187633A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12871399P 1999-04-08 1999-04-08
US128713P 1999-04-08
PCT/US2000/009255 WO2000061186A1 (en) 1999-04-08 2000-04-07 Use of anti-vegf antibody to enhance radiation in cancer therapy

Publications (2)

Publication Number Publication Date
EP1187633A1 EP1187633A1 (en) 2002-03-20
EP1187633A4 true EP1187633A4 (en) 2005-05-11

Family

ID=22436614

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00931923A Withdrawn EP1187633A4 (en) 1999-04-08 2000-04-07 Use of anti-vegf antibody to enhance radiation in cancer therapy

Country Status (3)

Country Link
EP (1) EP1187633A4 (en)
AU (1) AU4972900A (en)
WO (1) WO2000061186A1 (en)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
AU8473401A (en) 2000-08-04 2002-02-18 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
AU2003250701A1 (en) 2002-07-31 2004-02-16 Wayne R. Danter Protein tyrosine kinase inhibitors
ES2298563T3 (en) 2002-10-09 2008-05-16 Critical Outcome Technologies, Inc. INHIBITORS OF PROTEINS TIROSINA KINASAS.
ATE413393T1 (en) 2003-12-20 2008-11-15 Merck Patent Gmbh 2-(HETERO-)ARYL SUBSTITUTED TETRAHYDROCINOLINE DERIVATIVES
ATE550019T1 (en) 2005-05-17 2012-04-15 Merck Sharp & Dohme CIS-4-Ä(4-CHLOROPHENYL)SULFONYLÜ-4-(2,5-DIFLUOROPHENYL)CYCLOHEXANEPROPANE ACID FOR THE TREATMENT OF CANCER
DE102005061840A1 (en) 2005-12-23 2007-06-28 Merck Patent Gmbh New polyaza-benzo-azulene compounds are transforming growth factor-beta receptor kinase inhibitors used for treating e.g. cancer, HIV infection and Alzheimer's disease
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
JP2009531463A (en) * 2006-03-29 2009-09-03 ジェネンテック・インコーポレーテッド Tumor diagnosis and treatment
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EP2109608B1 (en) 2007-01-10 2011-03-23 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
MX2009009304A (en) 2007-03-01 2009-11-18 Novartis Ag Pim kinase inhibitors and methods of their use.
DE102007013856A1 (en) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituted tetrahydropyrroloquinolines
DE102007013855A1 (en) 2007-03-20 2008-09-25 Merck Patent Gmbh Substituted tetrahydroquinolines
DE102007013854A1 (en) 2007-03-20 2008-09-25 Merck Patent Gmbh Tetrahydroquinolines
CN101754965B (en) 2007-05-21 2014-03-19 诺华股份有限公司 CSF-1R inhibitors, compositions, and methods of use
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
DE102007047735A1 (en) 2007-10-05 2009-04-09 Merck Patent Gmbh thiazole
DE102007047737A1 (en) 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidine and piperazine derivatives
DE102007047738A1 (en) 2007-10-05 2009-04-09 Merck Patent Gmbh imidazole derivatives
DE102007049451A1 (en) 2007-10-16 2009-04-23 Merck Patent Gmbh 5-Cyano-thienopyridine
CA2709677C (en) 2007-12-21 2017-03-14 Lin Zhi Selective androgen receptor modulators (sarms) and uses thereof
EP2225226B1 (en) 2007-12-26 2016-08-17 Critical Outcome Technologies, Inc. Compounds and their use in a method for treatment of cancer
DE102008017853A1 (en) 2008-04-09 2009-10-15 Merck Patent Gmbh thienopyrimidines
US8466193B2 (en) 2008-04-15 2013-06-18 Pharmacyclics, Inc. Selective inhibitors of histone deacetylase
CA2730890C (en) 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
DE102008059578A1 (en) 2008-11-28 2010-06-10 Merck Patent Gmbh Benzo-naphthyridine compounds
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme Inhibitors of akt activity
MX2011010203A (en) 2009-04-02 2011-10-14 Merck Patent Gmbh Piperidine and piperazine derivatives as autotaxin inhibitors.
EA201101399A1 (en) 2009-04-02 2012-08-30 Мерк Патент Гмбх HETEROCYCLIC COMPOUNDS AS AUTOTAXIN INHIBITORS
US8329907B2 (en) 2009-04-02 2012-12-11 Merck Patent Gmbh Autotaxin inhibitors
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
DE102009033392A1 (en) 2009-07-16 2011-01-20 Merck Patent Gmbh Heterocyclic compounds as autotaxine inhibitors II
DE102009049211A1 (en) 2009-10-13 2011-04-28 Merck Patent Gmbh sulfoxides
EP2488028B1 (en) 2009-10-14 2020-08-19 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
WO2011054433A1 (en) 2009-11-07 2011-05-12 Merck Patent Gmbh Heteroarylaminoquinolines as tgf-beta receptor kinase inhibitors
EP2519517B1 (en) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
JP5675850B2 (en) 2010-02-05 2015-02-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Hetaryl- [1,8] naphthyridine derivatives
CN103097381B (en) 2010-02-22 2015-10-07 默克专利有限公司 As 1,8-naphthyridines material of kinase inhibitor
BR112012022868A2 (en) 2010-03-16 2018-06-05 Merck Patent Gmbh morpholinylquinazolines
BR112012023021A2 (en) 2010-03-16 2016-05-31 Dana Farber Cancer Inst Inc indazole compounds and their uses
AU2011232058B2 (en) 2010-03-26 2016-09-08 Merck Patent Gmbh Benzonaphthyridinamines as autotaxin inhibitors
EP3235818A3 (en) 2010-04-01 2018-03-14 Critical Outcome Technologies, Inc. Compounds for the treatment of hiv
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
ES2792799T3 (en) 2010-06-28 2020-11-12 Merck Patent Gmbh [1,8] 2,4-diaryl-substituted naphthyridines as kinase inhibitors for use against cancer
DE102010025786A1 (en) 2010-07-01 2012-01-05 Merck Patent Gmbh Pyrazolochinoline
BR112012033658A2 (en) 2010-07-05 2016-11-29 Merck Patent Gmbh bipyridyl derivatives useful for the treatment of kinase-induced diseases
CN103068980B (en) 2010-08-02 2017-04-05 瑟纳治疗公司 Using short interfering nucleic acid（siNA）The connection albumen led of mediated rnai（Cadherin related protein matter）, β 1（CTNNB1）The suppression of gene expression
KR102072631B1 (en) 2010-08-17 2020-02-03 시르나 쎄러퓨틱스 인코퍼레이티드 RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
DE102010035744A1 (en) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US8859775B2 (en) 2010-09-02 2014-10-14 Merck Patent Gmbh Pyrazolopyridinone derivatives as LPA receptor antagonists
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
US9051318B2 (en) 2011-03-09 2015-06-09 Merck Patent Gmbh Pyrido [2, 3-B] pyrazine compounds and their therapeutical uses such as for inhibiting ATP consuming proteins and treating diseases associated therewith
US20140046059A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Process for the preparation of morpholino sulfonyl indole derivatives
EP3925962A1 (en) 2011-05-31 2021-12-22 Rakovina Therapeutics Inc. Tricyclic inhibitors of poly(adp-ribose) polymerase
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP2822935B1 (en) 2011-11-17 2019-05-15 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
DE102011118830A1 (en) 2011-11-18 2013-05-23 Merck Patent Gmbh Morpholinylbenzotriazine
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
ES2651347T3 (en) 2012-11-28 2018-01-25 Merck Sharp & Dohme Corp. Compositions and methods for cancer treatment
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
DE102013008118A1 (en) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US20160264551A1 (en) 2013-10-18 2016-09-15 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
JO3589B1 (en) 2014-08-06 2020-07-05 Novartis Ag Protein kinase c inhibitors and methods of their use
WO2016105528A2 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US10550121B2 (en) 2015-03-27 2020-02-04 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP4019515A1 (en) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US11066396B2 (en) 2016-06-23 2021-07-20 Merck Sharp & Dohme Corp. 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
JOP20190055A1 (en) 2016-09-26 2019-03-24 Merck Sharp & Dohme Anti-cd27 antibodies
US10851164B2 (en) 2017-04-13 2020-12-01 Aduro Biotech Holdings, Europe B.V. Anti-SIRPα antibodies
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2021126731A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GORSKI D H ET AL: "Blockade of the Vascular Endothelial Growth Factor Stress Response Increases the Antitumor Effects of Ionizing Radiation", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, 15 July 1999 (1999-07-15), pages 3374 - 3378, XP002256383, ISSN: 0008-5472 *
LEE C G ET AL: "The effect of combined anti-VEGF mAb and radiation vs. radiation alone or anti-VEGF mAb alone on human tumor xenografts", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 40, March 1999 (1999-03-01), & 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; PHILADELPHIA, PENNSYLVANIA, USA; APRIL 10-14, 1999, pages 200, XP001204640, ISSN: 0197-016X *
See also references of WO0061186A1 *

Also Published As

Publication number Publication date
WO2000061186A1 (en) 2000-10-19
AU4972900A (en) 2000-11-14
EP1187633A1 (en) 2002-03-20

Similar Documents

Publication Publication Date Title
EP1187633A4 (en) Use of anti-vegf antibody to enhance radiation in cancer therapy
HK1038512A1 (en) Methods of inducing cancer cell death and tumor regression
HUS1500001I1 (en) Use of et743 in combination therapy with dexamethasone for treating cancer
HUP0203968A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
EP0926955A4 (en) Conjugates useful in the treatment of prostate cancer
PL368458A1 (en) Improved use of antitumoral compound in cancer therapy
HK1024876A1 (en) Conjugates useful in the treatment of prostate cancer
EP1320376A4 (en) Treatment of prostate cancer
IL147748A0 (en) Use of etodolac to treat cancer
EP1539197A4 (en) Treatment of tumor cells for use in immunotherapy of cancer
PL356770A1 (en) Use of anti-idiotypical antibodies as vaccines against cancer
IL156690A0 (en) Specific human antibodies for selective cancer therapy
IL136167A0 (en) Conjugates useful in the treatment of prostate cancer
EP1242071A4 (en) Use of parthenolide to inhibit cancer
AU2002351374A8 (en) Antibodies to treat cancer
AU2003302822A8 (en) Antibodies to treat cancer
PL371202A1 (en) Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine
EG22346A (en) Process for the preparation of conjugates useful in the treatment of prostate cancer
EP1427754A4 (en) Nucleic acid and polypeptide linked to breast cancer and uses therefor
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
IL149281A0 (en) Treatment of cancer
AU1576501A (en) Methods to enhance and confine gene expression in cancer therapy
GB0022216D0 (en) Human FAP-a-specific antibodies for use in cancer therapy
SI1229936T1 (en) Use of anti-idiotypical antibodies as vaccines against cancer
GB9907538D0 (en) Materials and methods relating to treatment of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011008

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050401

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE UNIVERSITY OF CHICAGO

Owner name: DANA-FARBER CANCER INSTITUTE, INC.

17Q First examination report despatched

Effective date: 20060512

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090514